ASXL1 and myeloid neoplasm: Whole-exome sequencing analyses revealed a 2.9% ASXL1 is mutation rate in CLL [246], with generally higher percentages in myeloid neoplasms (45.3% in CMML, 34.5% in MPN, 30% in secondary AML, 16.2% in MDS, and 6.5% in de novo AMLs) [247].